News

“This funding will help to accelerate the roll-out of acoustic blood cell sorting technology to industrial scale”‍ Aenitis Technologies, which develops new medical equipment based on acoustic manipulation of biological particles, today announced that it has received €4 million in funding, following its application to the highly-selective SME Instrument Phase 2 European programme, in the “Healthcare Biotechnology” category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171130005528/en/ SME Instrument Phase 2 is part of Horizon 2020, a programme managed by the European Commission and dedicated to innovation and research. It is part of the Industrial

Spin-off du CNRS et de l’ESPCI Paris, Aenitis Technologies développe des dispositifs médicaux de manipulation et de tri cellulaires basés sur l’utilisation de l’énergie acoustique. Ce mercredi, la société annonce la signature d’un partenariat avec la Direction générale de l’armement (DGA) pour mettre au point un nouveau processus de préparation des cellules stromales mésenchymateuses (CSM), les plus utilisées en médecine régénérative. En plein essor, la thérapie cellulaire génère des candidats médicaments prometteurs, mais se confronte à des difficultés de bioproduction. Pour les pallier, Aenitis Technologies développe des dispositifs médicaux de manipulation et de tri cellulaires basés sur

Une approche innovante pour optimiser les processus de bioproduction, via l’utilisation de la force acoustique, c’est ce que propose la start-up parisienne, hébergée au sein de l’hôpital Saint-Louis, Aenitis Technologies.  ‍ Focus sur les quatre segments dans lesquels la jeune entreprise compte bien faire son chemin. ‍ Acoustophorèse ou lévitation acoustique, telle est le nom de la méthode utilisée par la start-up Aenitis Technologies pour séparer, manipuler et filtrer des particules biologiques. Implantée à l’hôpital Saint-Louis de Paris, « pour disposer de l’expertise en thérapie cellulaire et de tout le matériel biologique nécessaire », comme

Success for some is the measure of wealth they have accumulated, while for some it is the respect they have earned. The word holds different meaning for different people. For Emmanuel Vincent, the Co-founder and CEO of Aenitis Technologies, it is the measure of how many lives he has saved or improved. Although, together we can move mountains but the strong determination and perseverance of one person can also make a difference in this world and that is what this 41-year young healthcare leader is set to do. Emmanuel is driven by activities involving social impact and is value creation oriented.

Paris, July 2, 2015 – Aenitis Technologies : Winner of 17th Contest in Category I-lab Creation Development of the Ministry of Research and Higher Education. Created in July 2014, Aenitis Technologies is a young French start-up from born from the work of Mauricio Hoyos and Jean-Luc AIDER, researchers at the CNRS Laboratory of Physics and Mechanics of Heterogeneous Media (PMMH) at ESPCI. The company focuses its activities in the medical devices sector where the impact of technology breaks it develops strongly wearer.. This significant support from the Ministry of Research and Higher Education will contribute

Paris, October 19, 2016 – Aenitis Technologies, a company that develops new medical devices based on acoustic manipulation mechanisms for biological particles, is announcing that FIST SA, the CNRS’ technology exploitation subsidiary, has acquired an interest in its capital ‍ France Innovation Scientifique et Transfert SA (FIST SA) has established a stake in the capital of the company founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, two CNRS research scientists working in the Laboratory of Physics and Mechanics of Heterogeneous Environments (CNRS, ESPCI, UPMC, Université Paris Diderot), and Emmanuel Vincent. Aenitis Technologies is

This funding will help to accelerate the roll-out of acoustic blood cell sorting technology to industrial scale Aenitis Technologies, which develops new medical equipment based on acoustic manipulation of biological particles, today announced that it has received €4 million in funding, following its application to the highly-selective SME Instrument Phase 2 European programme, in the “Healthcare Biotechnology” category. SME Instrument Phase 2 is part of Horizon 2020, a programme managed by the European Commission and dedicated to innovation and research. It is part of the Industrial Leadership pillar of H2020 and seeks to support fast-growing,